Latest CARDIEX (ASX:CDX) News

Cardiex Limited reported a 10% revenue increase in FY25, driven by new product launches and significant cost reductions, positioning the company for growth in FY26 with strong backing from C2 Ventures.

Cardiex Limited’s FY2025 results reveal a sharp 67% revenue decline driven by the prior year’s one-off clinical trial payment, while net losses nearly doubled despite ongoing cost reduction efforts and significant capital raises.

Cardiex reported strong growth in its Pulse arterial health monitor sales during Q4 FY25, surpassing A$0.7 million for the year and advancing its transition to subscription-based digital health services.

Cardiex Limited reported a $3 million cash outflow in Q4 2025 but is banking on cost reductions and new product sales to improve its financial footing. The company also secured $6.5 million through a capital raise to bolster its runway.

Cardiex Limited has successfully raised $4.1 million through a fully underwritten entitlement offer, bringing total funds raised to $6.5 million including a recent institutional placement. The offer saw strong participation from directors and key shareholders, with new shares set to be issued imminently.

Cardiex Limited has announced a fully underwritten 1-for-4 entitlement offer at $0.04 per share, aiming to raise approximately $4.1 million to advance manufacturing and scale its supply chain. The offer closes on 20 June 2025, following a recent $2.4 million placement.

Cardiex Limited has successfully raised $2.4 million through an institutional placement to boost manufacturing and commercial activities for its CONNEQT Pulse device.

Cardiex Limited has gained Therapeutic Goods Administration approval for its CONNEQT Pulse device, paving the way for commercial expansion in Australia alongside its established US presence.

Cardiex Digital Vascular Biomarkers announces a A$6.5 million equity raise to fund inventory, marketing, product development, and debt repayment, aiming to solidify its position in the expanding cardiovascular health market.

Cardiex Limited has raised $2.4 million through an institutional placement and launched a fully underwritten entitlement offer to raise up to $4.1 million, aiming to scale its CONNEQT Pulse device.

Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.

Cardiex reports strong early sales momentum for its CONNEQT Pulse device with approximately 3,000 units sold or contracted since its mid-January launch, supported by innovative app features and operational efficiencies. Despite regulatory delays in the US pharma sector and tariff challenges, the company is positioned for scalable growth and category leadership in preventative cardiovascular care.